Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration

Alexandra Keller, Zida Wu, Juergen Kratzsch, Eberhard Keller, Werner F Blum, Astrid Kniess, Rainer Preiss, Jens Teichert, Christian J Strasburger and Martin Bidlingmaier

Hospital for Children and Adolescents, University of Leipzig, Oststr. 21-25, D-04317 Leipzig, Germany, 1Division of Clinical Endocrinology, Department of Medicine, Charité University-Medicine, 10117 Berlin, Germany, 2Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, 61350 Leipzig, Germany, 3Eli Lilly & Co., Bad Homburg, Germany and Children’s Hospital, University of Giessen, 01731 Giessen, Germany, 4Institute of Doping Analysis and Sports Biochemistry, 04107 Kreischa, Germany, 5Institute of Clinical Pharmacology, University of Leipzig, Leipzig, Germany and 6Department of Internal Medicine, Ludwig Maximilian University of Munich, 80336 Munich, Germany

(Correspondence should be addressed to A Keller; Email: alexandra.keller@medizin.uni-leipzig.de)

Abstract

Objective: Pharmacokinetic and pharmacodynamic data after recombinant human GH (rhGH) administration in adults are scarce, but necessary to optimize replacement therapy and to detect doping. We examined pharmacokinetics, pharmacodynamics, and 20 kDa GH after injection of rhGH at different doses and routes of administration.

Design: Open-label crossover study with single boluses of rhGH.

Methods: Healthy trained subjects (10 males, 10 females) received bolus injections of rhGH on three occasions: 0.033 mg/kg s.c., 0.083 mg/kg s.c., and 0.033 mg/kg i.m. Concentrations of 22 and 20 kDa GH, IGF-I, and IGF-binding proteins (IGFBP)-3 were measured repeatedly before and up to 36 h after injection.

Results: Serum GH maximal concentration ($C_{\text{max}}$) and area under the time-concentration curve (AUC) were higher after i.m. than s.c. administration of 0.033 mg/kg ($C_{\text{max}}$ 35.5 and 12.0 mg/l; AUC 196.2 and 123.8). $C_{\text{max}}$ and AUC were higher in males than in females ($P<0.01$) and pharmacodynamic changes were more pronounced. IGFBP-3 concentrations showed no dose dependency. In response to rhGH administration, 20 kDa GH decreased in females and remained suppressed for 14–18 h (low dose) and 30 h (high dose). In males, 20 kDa GH was undetectable at baseline and throughout the study.

Conclusions: After rhGH administration, pharmacokinetic parameters are mainly influenced by route of administration, whereas pharmacodynamic variables and 20 kDa GH concentrations are determined mainly by gender. These differences need to be considered for therapeutic use and for detection of rhGH doping.

European Journal of Endocrinology 156 647–653

Introduction

In growth hormone (GH)-deficient adult patients, subcutaneous (s.c.) administration of recombinant human GH (rhGH) at a fixed dose results in less pronounced effects in females than in males (1–3). This is thought to be at least partly due to modulation of hepatic insulin-like growth factor-I (IGF-I) generation by endogenous and exogenous estrogens (4, 5). In addition, male and female patterns of fat distribution differ substantially and could potentially be associated with differences in absorption from the injection depot of rhGH (6, 7). The administration route in early studies of rhGH was by intramuscular (i.m.) injection; sex differences were not noted but these studies were in children who would not have developed adult differences between the sexes. The route was changed to the current standard of s.c. injection due to patient preference, but there were differences in absorption characteristics noted between the two routes of administration (8, 9). While pharmacokinetic data have been reported from early studies in children (8, 10), literature reports of pharmacokinetics in adults are scarce (11).

Unfortunately, rhGH has been misused, particularly in sport, and the methods to uncover such misuse have limitations (12, 13). Exogenously administered rhGH is structurally identical to endogenous 22 kDa GH, which is the isoform predominantly secreted in humans (14, 15). The most commonly used GH immunoassays recognize equally the 22 kDa isoform and the 20 kDa GH, which results from alternative splicing. It was
suggested that development of immunoassays that
could differentiate between the isoforms could be used
to assess misuse of rhGH (15).

The current study was designed to investigate the
pharmacokinetics and pharmacodynamics of rhGH in
recreationally trained adults after single dose injections
via s.c. and i.m. routes and to assess differences between
males and females. Pharmacokinetics of the 22 kDa
isoform were determined and pharmacodynamics were
assessed from changes in the serum concentrations of
the 20 kDa isoform, IGF-I, and IGF-binding proteins
(IGFBP)-3.

Subjects and methods

Subjects

Ten males and ten females were selected from a cohort
of 50 healthy young adults based on the level of sport
activities. Inclusion criteria were: aged 18–35 years,
body mass index (BMI) 19–27 kg/m², regular physical
exercise at least three times per week and, in females,
continuous use of oral contraceptives. Subjects were
excluded if they had any chronic illness, took any
medications known to interfere with endocrine func-
tion or reported any previous use of rhGH. Before
entering the study, a full physical examination was
performed and blood was taken for routine biochem-
isty, hematology, fasting blood glucose, and liver
enzymes. The local ethics committee of the University
of Leipzig, Germany, approved the protocol. All subjects
gave written informed consent and the study was
conducted in accordance with the principles of the
Declaration of Helsinki and the guidelines of good
clinical practice.

Study design

The study used a randomized crossover design. Subjects
were admitted to our clinical research unit for the three study periods, each starting at 0600 h
after an overnight fast. Intravenous catheters were
inserted in an antecubital vein and blood samples were
drawn at 60 and 0 min (baseline) before rhGH
administration then at 2-h intervals for the following
36 h. At 0 h, rhGH (Humatrope, Eli Lilly) was
administered as a bolus of either 0.033 mg/kg body
weight s.c., 0.083 mg/kg s.c. or 0.033 mg/kg i.m.,
according to a previously defined randomization
scheme. Over the three study periods, each patient
received each of the three rhGH doses in randomized
order; patients were blinded regarding the low and
high s.c. doses. Study periods were separated by a
washout of 4 weeks to synchronize with the menstrual
cycle in females.

Hormone measurements

Serum GH concentration was assayed by two sandwich
immunoassays. Assay 1 (mAb 3B4/biotinylated mAb
10A7) utilized a capture antibody, which preferentially
recognizes the monomeric 22 kDa isoform of GH, which is
identical to rhGH and the lower detection limit was
0.1 μg/l(12). Intraassay coefficients of variation were 6.5
and 4.8% at concentrations of 0.8 and 6.2 μg/l
respectively. Interassay coefficients of variation at the
same concentrations were 8.2 and 6.1% respectively (12).
Assay 2 was used for measuring the 20 kDa GH isoform
using two monoclonal antibodies with no cross-reactivity
to 22 kDa GH; intra- and interassay coefficients of
variation were 5.4 and 7.5% at 1 μg/l and the limit of
quantification was 0.05 μg/l(13). Assay 1 is referred to as
‘22 kDa GH’ while assay 2 is referred to as ‘20 kDa GH’.

Serum IGF-I was measured by an automated chemiluminescence immunoassay (Nichols Advantage
IGF-I, Nichols Institute Diagnostics, San Juan Capis-
trano, CA, USA) using acidification and IGF-II excess to
eliminate interference from IGFBP. Serum IGFBP-3 was
analyzed by a RIA described previously (16). All serum
samples were stored at −20 °C until analysis.

Calculation of pharmacokinetic and pharma-
codynamic parameters

Pharmacokinetic parameters were estimated using
standard noncompartmental analyses with the Win-
Nonlin pharamacokinetic software version 4.01 (Phar-
sight Corp., Mountain View, CA, USA).

Area under the time-concentration curve (AUClast)
was defined as the area under the curve from the time of
dosing to the last measurable concentration, calculated
using the linear trapezoidal rule. AUCinf was calculated
by extrapolation to infinity using the terminal half-life
(t1/2z) estimated with log-linear regression (AUCinf =
AUClast + AUCint). Mean residence time (MRT) was
calculated as the area under the first moment curve
(AUMC) divided by AUC. Apparent plasma clearance
(CL/F) was defined as the ratio of dose injected and AUC,
and apparent volume of distribution (Vz/F) was
calculated as (CL/F)/Dx (17).

Instead of total AUC, the increase of IGF-I or IGFBP-3
above baseline levels was used for calculating the
parameter ΔAUC 0–36.

Statistical methods

Data are given as mean ± s.d. or as median and
interquartile range (Q1, Q3). The GH concentrations
below the detection limit of the assays were assigned to
0 μg/l. Comparisons between sexes, dosages, and routes
of administration were performed with the Wilcoxon
test or the non-paired U-Mann–Whitney test as
indicated. Spearman rank correlation with two-tailed probability values was used to test the association between the variables. Statistical significance was assumed for $P < 0.05$. All statistical calculations were performed with Excel version 8.0 and SPSS version 11.0 for Windows (SPSS Inc., Chicago, IL, USA).

Results

Baseline characteristics

Baseline characteristics of the study subjects are shown in Table 1. Both 22 and 20 kDa GH at baseline were significantly higher in females than in males. In contrast, baseline serum IGF-I levels were significantly lower in females than in males. Differences between females studied in the follicular phase and in the luteal phase were not significant (data not shown).

Pharmacokinetics

Figure 1A depicts serum concentration profiles of 22 kDa GH over time in males and females by rhGH dose and route of administration. The pharmacokinetic parameters (Table 2) were not correlated with age or BMI at any dose or route of administration.

When the same rhGH dose (0.033 mg/kg) was administered, a significantly higher 22 kDa GH peak maximal concentration ($C_{\text{max}}$) and AUC were observed with the i.m. compared with s.c. route in males but not females. There was no difference between males and females for $C_{\text{max}}$ and AUC with s.c. rhGH, irrespective of the dose. In contrast, after i.m. administration mean $C_{\text{max}}$ and AUC were significantly higher in males than females, with a concomitantly lower CL/F in males. MRT was shorter in males than females in the low-dose group, irrespective of route of administration.

Pharmacodynamics: IGF-I and IGFBP-3 responses

Figure 1B and C show the time course of serum IGF-I and IGFBP-3 concentrations in males and females by rhGH dose and route of administration. Subjects with higher baseline IGF-I concentrations showed a greater response to rhGH than those with a lower baseline concentration ($P < 0.01$); this association was observed at all three study periods.

The increase from baseline integrated over time ($\Delta AUC_{0–36}$) was higher with the high dose for both IGF-I and IGFBP-3. There were no significant differences for IGF-I or IGFBP-3 parameters between s.c. and i.m. routes with the same rhGH dose. $T_{\text{max}}$ for serum IGF-I differed between males and females in the high-dose group. IGF-I $\Delta AUC_{0–36}$ showed a clear sex difference at the low dose, with higher values in males compared with females; this was independent of the route of administration. At the high dose, the difference between the sexes was not significant. IGFBP-3 $\Delta AUC_{0–36}$ was significantly higher in males than females at the low s.c. dose, while at the high s.c. dose similar values were observed (Table 3).

Pharmacodynamics: 20 kDa GH

At baseline, 20 kDa GH was detectable in all women in all three study periods; rapid suppression occurred after injection of rhGH (Fig. 2). In females, mean 20 kDa GH levels decreased from 0.4 at baseline to below 0.2 mg/l within 2 h after injection of rhGH. Duration of 20 kDa GH suppression in females was dose dependent: reoccurrence of 20 kDa GH secretion was observed in the low-dose s.c. group after 26 h, in the low-dose i.m. group after 28 h, and in the high dose s.c. group after 34 h. In contrast, in males 20 kDa GH levels were close to or below the lower limit of quantification (0.05 mg/l) of the assay at baseline and throughout the observation period.

Table 1  Baseline characteristics of the study subjects.

<table>
<thead>
<tr>
<th></th>
<th>Males</th>
<th>Females</th>
<th>$P^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>$N$</td>
<td>10</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>$b$Age (y)</td>
<td>24.2±3.1 (22; 29)</td>
<td>22.4±3.4 (19; 28)</td>
<td>Ns</td>
</tr>
<tr>
<td>$b$Height (cm)</td>
<td>184±9 (171; 202)</td>
<td>167±6 (161; 178)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>$b$Weight (kg)</td>
<td>83.1±14.6 (67; 107)</td>
<td>61.8±5.1 (55; 68)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>$b$Body mass index (kg/m²)</td>
<td>24.5±2.1 (21.1; 26.9)</td>
<td>22.0±2.0 (20.4; 24.8)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>$c$22 kDa GH (µg/l)</td>
<td>0.06 (0; 0.11)</td>
<td>0.02 (&lt;0.05; 0.07)</td>
<td></td>
</tr>
<tr>
<td>$c$20 kDa GH (µg/l)</td>
<td>0.02 (104; 255)</td>
<td>107.4 (75; 238)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>$c$IGFBP-3 (mg/l)</td>
<td>3.11 (2.4; 3.5)</td>
<td>2.98 (2.2; 3.7)</td>
<td>Ns</td>
</tr>
</tbody>
</table>

$^a$Wilcoxon signed rank test.

$^b$Mean ± s.d. (range).

$^c$Median (Q1/Q3).
Interdependence of pharmacokinetics and pharmacodynamics

The relationship between AUC for 22 kDa GH and ΔAUC 0–36 IGF-I was investigated by regression analysis. Combining all three study periods, the data sets (n = 30 per sex) showed normal distribution (Kolmogorov–Smirnov test, P < 0.05), thus allowing application of a linear regression model. A significant (P < 0.05) correlation was found between bioavailable GH and induced increase in IGF-I in both sexes, particularly with the high dose. At low GH AUC values, males showed higher IGF-I ΔAUC 0–36 than females; this difference was not seen at higher GH AUC values.

Adverse events

The most frequent adverse event was diarrhea occurring within 24 h after rhGH in six subjects receiving high dose and two subjects receiving low-dose s.c. injections. In four of the six subjects from the high-dose group, diarrhea was accompanied by moderate dizziness. Symptoms spontaneously ceased by the end of the study period (36 h). These episodes of diarrhea were not related to any identifiable causes such as dietary issues or gastrointestinal infections. Three subjects experienced enhanced sweating without obvious relation to the dose. One subject presented with decreased blood pressure, dizziness and vomiting 24 h after administration of the high dose; the symptoms resolved within 6 h. No edema was observed, and neither arthralgia nor headache was reported.

Discussion

The present data demonstrate that gender, dose and route of administration specifically alter bioavailability of and response to exogenous rhGH in healthy young adults. Pharmacokinetic variables were mainly influenced by the route of administration, whereas pharmacodynamic responses were primarily determined by sex. Furthermore, suppression of the 20 kDa GH isoform after injection of rhGH could be demonstrated only in women; 20 kDa GH levels in males were already low at baseline.

We assessed trained, but not elite level, subjects and highly trained individuals may respond differently to rhGH administration. With no exogenous rhGH, reduced serum IGF-I and IGFBP-3 concentrations have been reported during intense training (18, 19). The dose of rhGH used in this study was supraphysiological, because it can be assumed that illegal use by athletes will be at high doses (20). Physiological rhGH replacement in GH-deficient adults requires approximately one-third to one-fifth of the dose used in this study (21). Despite the high rhGH doses, we observed few of the side effects.
previously described in adults with GH deficiency (22, 23). However, a high frequency of diarrhea was seen, particularly after administration of the high rhGH dose. We found no explanation in regard to diet or gastrointestinal infections, and speculate that fluid regulation disturbances induced by the high dose could have caused the diarrhea (24).

Cmax and AUC were higher after i.m. than s.c. injection of the identical dose, in accordance with previous reports (25) indicating that serum GH after i.m. injection shows a higher amplitude and shorter duration compared with s.c. injection. Significant differences between males and females were found for GH Cmax and AUC after i.m., but not s.c. injection.

Table 2 Pharmacokinetic data of 22 kDa growth hormone (GH) by sex. Values are given as median (range).

<table>
<thead>
<tr>
<th>rhGH dose and route</th>
<th>Group A: 0.033 mg/kg s.c.</th>
<th>Group B: 0.033 mg/kg i.m.</th>
<th>Group C: 0.083 mg/kg s.c.</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC (h*μg/l)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>123.8 (68.1/435.2)</td>
<td>196.2 (110.4/476.1)</td>
<td>407.9 (206.7/546.8)</td>
</tr>
<tr>
<td>Males</td>
<td>134.9 (85.7/204.4)</td>
<td>209.2* (151.7/476.1)</td>
<td>413.5 (283.1/546.8)</td>
</tr>
<tr>
<td>Females</td>
<td>123.8 (68.1/435.2)</td>
<td>145.5* (110.4/308.4)</td>
<td>364.6 (206.7/476.6)</td>
</tr>
<tr>
<td>Maximal concentration (Cmax; μg/l)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>12.0 (5.5/32.7)</td>
<td>35.5 (14.3/85.7)</td>
<td>39.9 (19.9/74.2)</td>
</tr>
<tr>
<td>Males</td>
<td>15.5 (7.3/32.7)</td>
<td>41.8† (21.9/85.7)</td>
<td>47.8 (24.3/74.2)</td>
</tr>
<tr>
<td>Females</td>
<td>12.0 (5.5/22.6)</td>
<td>21.2† (14.3/54.2)</td>
<td>35.6 (19.9/72.1)</td>
</tr>
<tr>
<td>Terminal half-life (t1/2z; min)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>116.3 (31.6/262.1)</td>
<td>113.8 (72.0/235.8)</td>
<td>148.4 (101.0/234.7)</td>
</tr>
<tr>
<td>Males</td>
<td>130.4 (82.0/259.9)</td>
<td>106.3 (72.0/193.8)</td>
<td>144.8 (101.1/204.9)</td>
</tr>
<tr>
<td>Females</td>
<td>112.4 (31.6/262.1)</td>
<td>123.1 (76.9/235.8)</td>
<td>169.2 (115.5/234.7)</td>
</tr>
<tr>
<td>CL/F (ml/h/kg)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>261.7 (73.4/454.1)</td>
<td>209.1 (150.5/397.2)</td>
<td>224.3 (173.0/397.2)</td>
</tr>
<tr>
<td>Males</td>
<td>258.8 (161.1/381.7)</td>
<td>212.2* (184/288.4)</td>
<td>224.3 (173.0/397.2)</td>
</tr>
<tr>
<td>Females</td>
<td>261.7 (73.4/454.1)</td>
<td>197.8* (101.8/288.4)</td>
<td>224.3 (173.0/397.2)</td>
</tr>
</tbody>
</table>

*P <0.05, †P <0.01 for difference between males and females calculated by the U-Mann–Whitney test; Ns, not significant. Wilcoxon Test was used for between-group comparisons.

Table 3 Pharmacodynamics of insulin-like growth factor-I (IGF-I) and IGF-binding protein (IGFBP)-3 stratified by sex. Values are given as median (range).

<table>
<thead>
<tr>
<th>rhGH dose and route</th>
<th>A: 0.033 mg/kg s.c.</th>
<th>B: 0.033 mg/kg i.m.</th>
<th>C: 0.083 mg/kg s.c.</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGF-I</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tmax (h)</td>
<td>15.0 (6/30)</td>
<td>14.0 (8/28)</td>
<td>24.0 (14/24)</td>
</tr>
<tr>
<td>Males</td>
<td>21.0 (6/30)</td>
<td>19.0 (12/28)</td>
<td>28.0* (18/36)</td>
</tr>
<tr>
<td>Females</td>
<td>14.0 (6/22)</td>
<td>13.0 (8/18)</td>
<td>17.0* (14/28)</td>
</tr>
<tr>
<td>Cmax (μg/l)</td>
<td>302 (89/550)</td>
<td>303 (194/567)</td>
<td>413 (238/725)</td>
</tr>
<tr>
<td>Males</td>
<td>362 (267/550)</td>
<td>338 (238/567)</td>
<td>441 (346/725)</td>
</tr>
<tr>
<td>Females</td>
<td>234 (89/435)</td>
<td>230 (194/487)</td>
<td>351 (116/235)</td>
</tr>
<tr>
<td>ΔAUC 0–36 (h*μg/l)</td>
<td>79 (−14/178)</td>
<td>72 (−7/211)</td>
<td>136 (43/246)</td>
</tr>
<tr>
<td>Males</td>
<td>126* (86/178)</td>
<td>115* (50/211)</td>
<td>167 (134/246)</td>
</tr>
<tr>
<td>Females</td>
<td>26* (−14/84)</td>
<td>20* (−7/75)</td>
<td>104 (43/185)</td>
</tr>
<tr>
<td>IGFBP-3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔAUC 0–36 (h*μg/l)</td>
<td>121.6 (−116/580)</td>
<td>164.2 (−84/452)</td>
<td>285.4 (−122/664)</td>
</tr>
<tr>
<td>Males</td>
<td>172.5* (−102/580)</td>
<td>212.2* (−55/452)</td>
<td>271.7 (−60/664)</td>
</tr>
<tr>
<td>Females</td>
<td>82.5* (−116/390)</td>
<td>108.5* (−84/275)</td>
<td>302.2 (−122/716)</td>
</tr>
</tbody>
</table>

*P <0.05, †P <0.01 for difference between males and females calculated by the U-Mann–Whitney test. Wilcoxon test was used for between-group comparison.
Although one could have expected a higher $t_{1/2z}$ after s.c. administration in women, due to the higher s.c. fat (26), $t_{1/2z}$ was not affected by gender, perhaps because the women in the study were trained and lean. The increase in IGF-I was positively correlated to baseline concentration, and was not affected by route of administration. Compared to IGFBP-3, the increase in serum IGF-I was faster and more pronounced, consistent with previous publications indicating that the ratio of IGF-I/IGFBP-3 increases immediately after rhGH injection (27). The increase in IGFBP-3 was delayed, not clearly dose dependent and did not return to baseline during the observation period, confirming that IGF-I is a more sensitive marker of GH action in trained adults than IGFBP-3.

The increase in IGF-I, but not the increase in IGFBP-3, shows a marked sexual dimorphism. Integrated IGF-I release after rhGH injection was significantly higher in males than females, whereas $T_{\text{max}}$ and $C_{\text{max}}$ did not differ between sexes. IGF-I and IGFBP3 response is higher in males at low dose. However, it might be the case that the high dose of rhGH being a stronger stimulus also evokes a higher response in females. The difference between sexes is of course most likely due to the influence of estrogens, as all females were on oral contraceptives. No clear difference was seen in IGF-I response but the study was not specifically designed to investigate the impact of estrogens. It has been proposed that use of oral estrogens interferes with hepatic IGF-I production, but women not using estrogen supplementation also exhibit a lower IGF-I response than males (1). Studies in animals indicate that complex mechanisms, including modification of hepatic GH receptor expression, lead to the sexual dimorphism in the somatotropic axis (28). In contrast to serum GH concentrations, IGF-I and IGFBP-3 concentrations did not return to pre-treatment levels within the observation period, supporting the idea of use of these markers to detect doping with rhGH (13, 27, 29).

The existing studies on the relationship between 22 kDa and 20 kDa isoforms suggest that the secretion is a part of constant percentage of total GH. Therefore, the lower 20 kDa level and the long-term suppression in males seem to be a consequence of the lower total GH concentration. The 20 kDa GH isoform was also suppressed in females after administration of rhGH, consistent with a negative feedback of exogenous rhGH on pituitary GH secretion; the duration of suppression was dose dependent and re-occurrence of 20 kDa in the circulation was seen 26–28 h after low-dose rhGH and 34 h after high dose rhGH. The prolonged changes provide further evidence that the GH isoform pattern can be used to detect the administration of rhGH in males. With the assay method used in this study, 20 kDa GH levels in males were almost undetectable, making it impossible to demonstrate further suppression. Thus, more sensitive assays to quantify the amount of 20 kDa GH are necessary.

In summary, our data show that in healthy trained adults, responsiveness to rhGH administration is regulated by a variety of factors. Pharmacokinetic parameters are mainly influenced by the route of administration, with higher GH $C_{\text{max}}$ and AUC after i.m. injection, while pharmacodynamic parameters are mainly determined by gender. These differences need to be considered when decisions are made regarding therapeutic dosing with rhGH. Changes in the molecular isoforms in circulation after injection of rhGH show that in females, measurement of 20 kDa GH could be a useful parameter to detect rhGH doping in athletes.

**Acknowledgements**

We thank all subjects for their full co-operation. Furthermore, we are grateful to the nurses and accompanying persons of the Endocrine Research Unit of the Hospital for Children and Adolescents, University of Leipzig, Germany. Additionally, we thank Dr Götz Gelbrich (Center of Coordination of Clinical Studies, University of Leipzig, Germany) for his support in data management. This study was supported by the National Institute of Sports Research (BISp), Bonn, Germany and by Eli Lilly Company, Bad Homburg, Germany.
References


Received 27 January 2007 Accepted 14 March 2007

www.eje-online.org